Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dronedarone→

Dronedarone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
141626-36-0
Molecular formula
C31H44N2O5S
Molecular weight
556.8 g/mol
Drug class
Multichannel antiarrhythmicclass III-like rhythm-control agent
Mechanism of action
Inhibits multiple ion channels, including potassium, sodium and calcium currents, and has antiadrenergic effects, prolonging cardiac action potential and refractoriness while slowing conduction.
Indications / reported uses
  • Reduction of risk of hospitalisation for atrial fibrillation in adults with a history of paroxysmal or persistent atrial fibrillation who are in sinus rhythm or will be cardioverted; contraindicated in permanent AF and certain heart failure settings

Sources: US DailyMed — MULTAQ (dronedarone) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Multichannel antiarrhythmic; class III-like rhythm-control agent

Mechanism of action

Inhibits multiple ion channels, including potassium, sodium and calcium currents, and has antiadrenergic effects, prolonging cardiac action potential and refractoriness while slowing conduction.

General use cases

  • Reduction of risk of hospitalisation for atrial fibrillation in adults with a history of paroxysmal or persistent atrial fibrillation who are in sinus rhythm or will be cardioverted; contraindicated in permanent AF and certain heart failure settings

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Dronedarone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dronedarone Permitted Daily Exposure (PDE) report (the Dronedarone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dronedarone Occupational Exposure Limit (OEL) report (the Dronedarone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.